Approval from the UK for the use of Pfizer’s COVID-19 pill

2 mins read
UK for the use of Pfizer's COVID-19 pill

Approval from the UK for the use of Pfizer’s COVID-19 pill

Pfizer’s Covid-19 pill has been approved for use in the UK for patients over the age of 18 who have mild to moderate disease but are at high risk of worsening.

UK for the use of Pfizer's COVID-19 pillIn the statement made by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), it was stated that the pill is most effective when taken in the early stages of Covid-19, and it is recommended to use the drug within 5 days from the onset of symptoms.

On the other hand, it was emphasized that it is too early to know whether the Omicron variant has any effect on the effectiveness of Paxlovid, but it was noted that MHRA is proactively working with Pfizer to determine this.

The statement also underlined that the pill taken after being infected with the virus does not replace the vaccines, and called for the public to have the Covid-19 vaccines.

“Paxlovid reduces hospitalizations and deaths related to COVID-19 by 89 percent”

MHRA President Dr. “Today we granted regulatory approval for Paxlovid, a COVID-19 treatment that has been found to reduce COVID-19-related hospitalizations and deaths by 89 percent when taken within 3 days of symptom onset,” June Raine said in a statement. used the phrase.

In a statement made by Pfizer on December 14, it was stated that Paxlovid had an effect of approximately 90 percent in preventing hospitalizations and deaths in high-risk patients.

It was also pointed out that the latest laboratory data maintains the effectiveness of the drug against the rapidly spreading Omicron variant of Covid-19.

On 2 December in England, the use of the monoclonal antibody drug Xevudy (sotrovimab), which was found to reduce the probability of hospitalization and death due to Covid-19 by 79 percent, was approved.


The ancient idea tries to provide the most accurate information to its readers in all the content it publishes.